INT93490

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 2000
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 3.14
Pain Relevance 9.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
brain 2
liver 1
embryonic kidney 1
oocytes 1
GPM6A (Homo sapiens)
Pain Link Frequency Relevance Heat
Morphine 268 100.00 Very High Very High Very High
opioid receptor 45 100.00 Very High Very High Very High
opiate 11 99.68 Very High Very High Very High
agonist 13 99.40 Very High Very High Very High
mu opioid receptor 4 99.16 Very High Very High Very High
antinociception 4 99.00 Very High Very High Very High
Bioavailability 1 98.38 Very High Very High Very High
Analgesic 54 97.84 Very High Very High Very High
Potency 14 97.44 Very High Very High Very High
Pain 156 96.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cirrhosis 331 97.96 Very High Very High Very High
Pain 175 96.84 Very High Very High Very High
Renal Insufficiency 4 94.92 High High
Toxicity 4 92.52 High High
Cancer 69 86.32 High High
Myoclonus 3 84.96 Quite High
Frailty 2 71.04 Quite High
Apoptosis 39 68.16 Quite High
Constipation 6 62.40 Quite High
Vomiting 17 57.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Morphine-6beta-glucuronide (M6G), a metabolite of morphine that the brain can produce, is an opiate agonist that appears to have a greater analgesic potency than morphine.
Gene_expression (produce) of M6G in brain associated with analgesic, agonist, opiate, potency and morphine
1) Confidence 0.69 Published 2005 Journal Med. Sci. Monit. Section Abstract Doc Link 15874899 Disease Relevance 0 Pain Relevance 1.01
This study was performed to develop an integrated pharmacokinetic-pharmacodynamic model for estimating the contribution of morphine-6-glucuronide (M6G) to morphine-associated antinociception in humans.
Gene_expression (contribution) of M6G associated with antinociception and morphine
2) Confidence 0.43 Published 2002 Journal J Clin Pharmacol Section Abstract Doc Link 12017351 Disease Relevance 0.08 Pain Relevance 0.76
On the other hand, overexpression of a M6a-negative mutant prevents mu-opioid receptor endocytosis, demonstrating an essential role of M6a in receptor internalization.
Gene_expression (overexpression) of M6a associated with opioid receptor
3) Confidence 0.41 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17548356 Disease Relevance 0 Pain Relevance 0.76
Co-expression of MOPr with M6a, but not with M6b or DM20, exists in many brain regions, further supporting a specific interaction between MOPr and M6a.
Gene_expression (Co-expression) of M6a in brain associated with opioid receptor
4) Confidence 0.36 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17548356 Disease Relevance 0 Pain Relevance 0.65
Bioluminescence resonance energy transfer and co-immunoprecipitation experiments confirmed that M6a interacts agonist-independently with MOPr in human embryonic kidney 293 cells co-expressing MOPr and M6a.
Gene_expression (co-expressing) of M6a in embryonic kidney associated with agonist and opioid receptor
5) Confidence 0.36 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17548356 Disease Relevance 0 Pain Relevance 0.64
Serum concentrations of morphine and M6G were determined by LC/MS.
Gene_expression (concentrations) of M6G associated with morphine
6) Confidence 0.33 Published 2002 Journal J Clin Pharmacol Section Abstract Doc Link 12017351 Disease Relevance 0.10 Pain Relevance 1.12
RESULTS: Morphine and M6G produced significant pain relief compared with placebo (morphine, P < .0001; M6G, P = .033).
Gene_expression (produced) of M6G
7) Confidence 0.18 Published 2000 Journal Clin. Pharmacol. Ther. Section Body Doc Link 11180027 Disease Relevance 0 Pain Relevance 0
Morphine, M6G and M3G serum concentrations
Gene_expression (Morphine) of M6G associated with morphine
8) Confidence 0.10 Published 2004 Journal BMC Clin Pharmacol Section Body Doc Link PMC526195 Disease Relevance 0.06 Pain Relevance 1.60
Narrow ranges were used for the detection of morphine and M6G, 3.5 to 50 nmol/L and 5.0 to 1000 nmol/L, respectively.
Gene_expression (detection) of M6G associated with morphine
9) Confidence 0.04 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376067 Disease Relevance 0 Pain Relevance 0.48
In cirrhosis, the bioavailability of morphine is increased due to the lack of first pass metabolism; however, the production of the more potent M6G metabolite may decrease resulting in a less than optimal analgesic effect.
Gene_expression (production) of M6G associated with cirrhosis, analgesic, morphine and bioavailability
10) Confidence 0.02 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386360 Disease Relevance 0.76 Pain Relevance 1.19
Using heterologous expression in Xenopus laevis oocytes, we compared the potencies of morphine, morphine-6beta-glucuronide (M6G), and morphine-3-glucuronide (M3G) for cloned human mu- (hMOR), kappa- (hKOR), and delta-opioid receptors (hDOR).
Gene_expression (expression) of M6G in oocytes associated with delta opioid receptors and morphine
11) Confidence 0.02 Published 2001 Journal Biochem. Pharmacol. Section Abstract Doc Link 11705461 Disease Relevance 0 Pain Relevance 0.75
Respectively, 86 and 63% of the dose of 15dPGJ2-M6PHSA and 15dPGJ2-pPBHSA was present in the liver already 15 min after intravenous injection.
Gene_expression (present) of M6PHSA in liver
12) Confidence 0.01 Published 2007 Journal Pharm Res Section Body Doc Link PMC1915609 Disease Relevance 0.75 Pain Relevance 0.03
Subsequently, 15dPGJ2, 15dPGJ2-M6PHSA, M6PHSA, 15dPGJ2-pPBHSA or pPBHSA were added in increasing concentrations and the cells were incubated with or without 10% FCS for another 18 h.
Gene_expression (added) of M6PHSA
13) Confidence 0.00 Published 2007 Journal Pharm Res Section Body Doc Link PMC1915609 Disease Relevance 0.70 Pain Relevance 0.05
Subsequently, 15dPGJ2, 15dPGJ2-M6PHSA, M6PHSA, 15dPGJ2-pPBHSA or pPBHSA were added in increasing concentrations and the cells were incubated with or without 10% FCS for another 18 h.
Gene_expression (added) of M6PHSA
14) Confidence 0.00 Published 2007 Journal Pharm Res Section Body Doc Link PMC1915609 Disease Relevance 0.70 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox